Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain.

MLA

Martín García-Sancho, Alejandro, et al. “Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain.” Cancers, vol. 16, no. 13, July 2024, p. 2301. EBSCOhost, https://doi.org/10.3390/cancers16132301.

APA

Martín García-Sancho, A., Presa, M., Pardo, C., Martín-Escudero, V., Oyagüez, I., & Ortiz-Maldonado, V. (2024). Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain. Cancers, 16(13), 2301. https://doi.org/10.3390/cancers16132301

Chicago

Martín García-Sancho, Alejandro, María Presa, Carlos Pardo, Victoria Martín-Escudero, Itziar Oyagüez, and Valentín Ortiz-Maldonado. 2024. “Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain.” Cancers 16 (13): 2301. doi:10.3390/cancers16132301.